[Table_Info1] [Table_Title] 证券研究报告 / 公司点评报告 H1 业绩稳健增长，高毛利产品占比提升 --- 2025 年中报点评 [Table_Summary] 事件：据公司公告，2025 上半年公司实现营收 12.47 亿元，同比-3.64%， 归母净利润 4.45 亿元，同比+10.01%，扣非归母净利润 4.36 亿元，同比 +11.08%。 点评 高附加值业务占比提升，叠加原材料价格回落，盈利能力显著提升 2025 年 H1 公司实现毛利率 51.26%（同比+3.78pct），净利率 35.97%（同 比+4.32pct），盈利能力显著提升主要得益于生命科学、金属资源、超纯 水等高毛利业务占比提升，体现了公司的技术优势；同时，报告期内苯 乙烯等主要原材料价格有所回落。公司经营性现金流净额为 2.88 亿元 （同比+36.50%），期末资产负债率为 36.30%，有息负债保持在较低水平。 基本仓业务发展稳健，生命科学、金属资源、水处理业务维持高增态势 2025 年 H1，公司实现营收 12.47 亿元（同比下降 3.64%），主要系报告 期内盐湖提锂大型项目未确认收入。扣除 ...

Financial Performance - In the first half of 2025, the company achieved revenue of 1.247 billion CNY, a year-on-year decrease of 3.64% [2] - The net profit attributable to shareholders was 445 million CNY, reflecting a year-on-year increase of 10.01% [2] - The overall gross profit margin was 51.26%, up by 3.8 percentage points compared to the previous year [4] - The cash flow from operating activities was 288 million CNY, an increase of 36.50% year-on-year [2] - The debt-to-asset ratio stood at 36.30%, indicating a stable financial condition [2] Business Development - The company plans to establish a high-end materials industrial park in the life sciences sector, covering an area of 270 acres with a total investment of 1.15 billion CNY [3] - The product range will include chromatography media, polymer chromatography fillers, enzyme carriers, and various adsorption separation materials [3] Profitability Insights - The gross margin for adsorption materials was 54.27%, an increase of 3.2 percentage points, driven by a higher proportion of high-margin businesses [4] - The decline in prices of key raw materials, such as styrene, contributed to the improved gross margin [4] Lithium Projects - In the first half of 2025, there was no revenue recognition from large-scale lithium extraction projects, but other lithium-related business generated approximately 61 million CNY [5] - The company secured a contract worth 35.77 million CNY for a lithium extraction system from Guotou Luojia [5] Market Position - The company remains a leading supplier in the solid-phase synthesis carrier market, primarily serving CDMO enterprises [6] - The competitive landscape for solid-phase synthesis carriers has not changed significantly [6] International Expansion - The company has seen significant growth in overseas revenue, with an increasing proportion of international business [7] - The establishment of subsidiaries, warehouses, and laboratories in various countries supports the company's global market expansion [7]

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6]. Core Views - The company reported a revenue of 2.554 billion yuan in 2024, a year-on-year increase of 2.6%, and a net profit attributable to the parent company of 787 million yuan, up 9.8% year-on-year [1]. - The revenue from the lithium extraction project significantly declined, impacting the overall performance of the system equipment segment, while the adsorption materials business showed robust growth [2][3]. - The life sciences segment is expected to continue its growth trajectory, driven by the demand for high-quality solid-phase synthesis carriers and the performance of GLP-1 peptide drugs [3]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 662 million yuan, down 27.4% year-on-year, but up 10.89% quarter-on-quarter, with a net profit of 191 million yuan, down 4.0% year-on-year [1]. - For Q1 2025, the company reported a revenue of 577 million yuan, a decrease of 8.6% year-on-year and 12.91% quarter-on-quarter, while the net profit was 193 million yuan, an increase of 14.2% year-on-year [1]. Business Segments - The adsorption materials business generated 1.986 billion yuan in revenue, up 27.61% year-on-year, while the system equipment segment saw a revenue decline of 43.13% to 469 million yuan [2]. - The revenue from the lithium extraction system equipment was only 99 million yuan in 2024, a dramatic drop of 80.96% compared to 520 million yuan in 2023 [2]. Growth Areas - The life sciences segment's revenue reached 568 million yuan in 2024, reflecting a growth of 28% [3]. - The ultra-pure water segment achieved significant breakthroughs, with substantial orders from key semiconductor companies, indicating a growing market presence [3]. Profitability Forecast - The net profit forecasts for 2025-2027 are adjusted to 1.127 billion yuan, 1.463 billion yuan, and 1.706 billion yuan, respectively, maintaining the "Buy" rating [3].

Core Viewpoint - The company reported steady revenue and profit growth in 2024, with a notable performance in its core business segments, despite challenges in specific projects like the lithium extraction project [1][3]. Financial Performance Summary - In 2024, the company achieved revenue of 2.554 billion yuan, a year-on-year increase of 2.62%, and a net profit attributable to shareholders of 787 million yuan, up 9.79% year-on-year [1]. - The weighted average return on equity was 21.33%, down 1.79 percentage points year-on-year [1]. - The gross profit margin was 49.47%, an increase of 0.80 percentage points year-on-year, while the net profit margin was 31.11%, up 2.12 percentage points year-on-year [1]. - In Q4 2024, revenue was 662 million yuan, a year-on-year decrease of 27.40%, but a quarter-on-quarter increase of 10.89% [1]. - For Q1 2025, revenue was 577 million yuan, down 8.58% year-on-year and 12.91% quarter-on-quarter, while net profit was 193 million yuan, up 14.18% year-on-year [2]. Business Segment Performance - The lithium extraction project generated revenue of 99 million yuan in 2024, a significant decline of 80.96% year-on-year, primarily due to cyclical industry conditions and project execution delays [3]. - Excluding the lithium project, the core business achieved revenue of 2.455 billion yuan, a year-on-year increase of 24.71%, indicating strong growth momentum [3]. - Key segments such as water treatment and ultrapure water, life sciences, and metal resources reported revenues of 688 million, 568 million, and 256 million yuan, respectively, with year-on-year growth rates of 34%, 28%, and 30% [3]. - The chemical and catalysis, and food processing segments also showed strong performance, with revenues of 202 million and 56 million yuan, reflecting year-on-year increases of 42% and 28% [3]. Growth Drivers and Strategic Initiatives - The water treatment and ultrapure water business saw significant breakthroughs, with sales reaching 688 million yuan, a 34% increase year-on-year, driven by increased market penetration and long-term contracts with major clients [4]. - The life sciences segment is benefiting from the strong market performance of GLP-1 peptide drugs, leading to rapid growth in solid-phase synthesis carrier business [5]. - The company is expanding its international marketing and technical service network, enhancing its local team in North America and Europe, and investing in capacity expansion and upgrades to support long-term growth [5]. Profit Forecast and Valuation - The company is projected to achieve net profits of 1.026 billion, 1.283 billion, and 1.576 billion yuan for 2025-2027, with corresponding EPS of 2.02, 2.53, and 3.10 yuan [6]. - The current price corresponds to PE ratios of 22.85, 18.26, and 14.87 for the respective years, indicating a favorable long-term growth outlook [6].

Core Viewpoint - Blue Sky Technology (300487.SZ) has achieved steady growth amidst the global trend of self-sufficiency in the new materials industry and accelerated domestic high-end manufacturing [1] Financial Performance - In 2024, the company reported total revenue of 2.554 billion yuan, a year-on-year increase of 2.62% [1] - Net profit attributable to shareholders reached 787 million yuan, reflecting a year-on-year growth of 9.79% [1] - The increase in net profit outpaced revenue growth, indicating an improvement in the profit structure due to a higher proportion of high-value-added businesses [1] Business Segments - The core growth driver is the adsorption materials segment, which maintained a high gross margin [1] - Basic warehouse business showed stable growth, while life sciences, metal resources, water treatment, and ultra-purification segments experienced significant growth [1] - Basic business revenue reached 2.45 billion yuan, a year-on-year increase of 24.7%, accounting for 96.1% of total revenue [3] Key Business Highlights - Sales revenue from core adsorption materials was 1.99 billion yuan, representing 80.9% of total revenue [4] - The metal resources segment saw sales revenue of 256 million yuan, a year-on-year increase of 30% [4] - Life sciences segment revenue reached 568 million yuan, growing by 28% [5] - Water treatment and ultra-purification segment achieved sales revenue of 688 million yuan, a year-on-year increase of 34% [5] - Chemical and catalytic segment sales reached 202 million yuan, up 42% year-on-year [5] Strategic Focus - The company aims to maintain stable growth in its basic warehouse business and ensure high-quality delivery of major projects like the Tibet Jiezhe project [1][7] - The internationalization strategy will be a key focus area moving forward [1] - The company plans to allocate resources according to the characteristics of its business segments, with metal resources and life sciences being priority areas [7] Market Opportunities - Emerging markets in life sciences, drinking water, new energy, and carbon emissions are expected to open new demand increments, providing a new supply-demand window for domestic upstream suppliers [6] - The company is expanding its local teams in North America and Europe to enhance competitiveness in international markets [5][8] - The establishment of a wholly-owned subsidiary in the U.S. aims to facilitate localized business development [8]